Overview
- The market has rerated higher this year with the S&P 500 up about 11 percent on a tech-led rally, while geopolitical strains such as the war in Iran, rising oil and interest-rate concerns have added volatility.
- AbbVie is highlighted for a forward price-to-earnings ratio near 15, roughly $20 billion of trailing 12-month free cash flow and a roughly 3.3 percent dividend yield, features analysts say support its buy case even though its shares are down year to date.
- CVS Health’s outlook improved after a stronger-than-expected first-quarter report and an upgraded full-year guide that helped restore investor confidence in its insurance and pharmacy businesses and has lifted the stock this year.
- Verizon is offered as a third pick for investors seeking income and relative value inside large-cap stocks, with commentators emphasizing its steady dividend as a defensive source of cash flow.
- The broader take is that income-paying large caps with clear cash flow and improving company-specific fundamentals may offer downside protection and income for portfolios when the overall index looks expensive.